| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biophys J, July 1999, p. 189-203, Vol. 77, No. 1
Muscle Research Group, John Curtin School of Medical Research, Canberra, ACT 2601, Australia
| |
ABSTRACT |
|---|
|
|
|---|
Peptides, corresponding to sequences in the N-terminal
region of the skeletal muscle dihydropyridine receptor (DHPR) II-III loop, have been tested on sarcoplasmic reticulum (SR) Ca2+
release and ryanodine receptor (RyR) activity. The peptides were: A1,
Thr671-Leu690; A2,
Thr671-Leu690 with Ser687 Ala
substitution; NB, Gly689-Lys708 and A1S,
scrambled A1 sequence. The relative rates of peptide-induced Ca2+ release from normal (FKBP12+) SR were A2 > A1 > A1S > NB. Removal of FKBP12 reduced the rate of
A1-induced Ca2+ release by ~30%. A1 and A2 (but not NB
or A1S), in the cytoplasmic (cis) solution, either
activated or inhibited single FKBP12+ RyRs. Maximum activation was seen
at
40 mV, with 10 µM A1 or 50 nM A2. The greatest A1-induced
increase in mean current (sixfold) was seen with 100 nM
cis Ca2+. Inhibition by A1 was greatest at
+40 mV (or when permeant ions flowed from cytoplasm to SR lumen) with
100 µM cis Ca2+, where channel activity
was almost fully inhibited. A1 did not activate FKBP12-stripped RyRs,
although peptide-induced inhibition remained. The results show that
peptide A activation of RyRs does not require DHPR Ser687,
but required FKBP12 binding to RyRs. Peptide A must interact with
different sites to activate or inhibit RyRs, because current direction-, voltage-, cis [Ca2+]-, and
FKBP12-dependence of activation and inhibition differ.
| |
INTRODUCTION |
|---|
|
|
|---|
The ryanodine receptor (RyR) calcium channel
mediates Ca2+ release from internal stores in many cell
types and is an essential component of excitation-contraction coupling
(ECC) in striated muscle. In skeletal muscle, the L-type
Ca2+ channel (dihydropyridine receptor, DHPR) is the
voltage sensor for ECC, i.e., it senses T-tubule depolarization and
transmits a signal to the RyR, via a protein-protein interaction which
requires the loop between the second and third repeats of the skeletal DHPR
1 subunit (II-III loop; Tanabe et al., 1990
). The
II-III loop of the DHPR binds to a 37-amino acid sequence,
Arg1076-Asp1112, in the skeletal muscle RyR
(Leong and Maclennan, 1998
).
The skeletal DHPR II-III loop increases [3H]ryanodine
binding to sarcoplasmic reticulum (SR) vesicles, and activates purified RyR channels in lipid bilayers (Lu et al., 1994
, 1995
). Because ryanodine binds preferentially to open RyR channels, the increase in
[3H]ryanodine binding suggests that native RyRs in SR
vesicles are activated by the II-III loop. The N-terminal part of the
II-III loop (Glu666-Glu726) also activates RyR
channels, but fails to do so when Ser687 is either
phosphorylated or replaced by alanine (Lu et al., 1995
). A short
peptide Thr671-Leu690 (peptide A) activates
Ca2+ release from SR, but peptides corresponding to other
segments of the loop do not (El-Hayek et al., 1995
; El-Hayek and
Ikemoto, 1998
). Since the actions of peptide A on single RyR channels
had not been reported, we examined its effects on RyRs. We also studied possible interactions between the regulation of RyRs by peptide A and
their regulation by the FK506-binding protein (FKBP12), a co-protein
that coordinates RyR activity. FKBP12 is intrinsic to normal RyR
function and may be involved in ECC (Ahern et al., 1994
, 1997a
;
Brillantes et al., 1994
; Mayrleitner et al., 1994
; Lamb and Stephenson,
1996
). Four FK506-binding proteins (FKBP12, Mr
~12,000) are tightly bound to each RyR monomer (Jayaraman et al.,
1992
; Timerman et al., 1993
; Wagenknecht et al., 1996
, 1997
). The
immunosuppressant drugs FK506 and rapamycin bind to FKBP12 and
dissociate it from the RyR (Timerman et al., 1993
, 1995
). RyRs
"stripped" of their FKBP12 co-proteins display increased channel
activity at low cytoplasmic Ca2+ concentrations, with a
loss of coordinated channel opening to the maximum conductance (Ahern
et al., 1997a
).
In this study, the ability of peptide A1
(Thr671-Leu690) and peptide A2 (with
Ser687 replaced by Ala687) to release
Ca2+ from native FKBP12+ terminal cisternae (TC) vesicles
and from FKBP12-stripped vesicles was examined, as well as the actions of the peptides on single native RyR channels incorporated into lipid
bilayers. The results showed that peptide A1 released Ca2+
from FKBP12+ and FKBP12-stripped TC vesicles, although release from the
RyRs lacking FKBP12 was markedly reduced. Ca2+ release by
peptide A2 was greater than that by peptide A1. The peptides had a dual
action on RyR channel activity. Activation at
40 mV was greatest with
100 nM cis Ca2+, while inhibition at +40 mV was
strongest with 100 µM cis Ca2+. Channel
activation by the peptide was markedly reduced in FKBP12-stripped RyRs.
The inhibition of channel activity was strongest when current flowed
from the cytoplasmic to the luminal side of the RyR and preferentially
blocked channel opening to maximum conductance levels. The results show
that these small DHPR II-III loop peptides can both activate and
inhibit single RyR channels and are likely to act on at least two
separate sites on the RyR channel protein.
| |
METHODS |
|---|
|
|
|---|
Materials
Rapamycin was obtained from Calbiochem and as a gift from Wyeth-Ayerst (Princeton, NJ). Other chemicals and biochemicals were from Sigma-Aldrich (Castle Hill, Australia). The DHPR II-III loop peptides were synthesized using an Applied Biosystems 430A Peptide Synthesiser with purification to 98 to 100% using HPLC and mass spectroscopy. Peptide conformation was determined using NMR. Stock peptide solutions (~2 mM) were prepared in H20 and frozen in 20-µl aliquots. Precise stock solution concentrations were determined (Auspep Pty Ltd) using acid hydrolysis followed by a standardized PTC (phenylthiocarbamyl) protocol and analyzed by reverse phase HPLC. The following peptides were used in this study.
Peptide A1
671Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ser Arg Gly Leu690.Peptide A2
671Thr Ser Ala Gln Lys Ala Lys Ala Glu Glu Arg Lys Arg Arg Lys Met Ala Arg Gly Leu690.Peptide NB
689Gly Leu Pro Asp Lys Thr Glu Glu Glu Lys Ser Val Met Ala Lys Lys Leu Glu Gln Lys708.Peptide A1S
Thr Arg Lys Ser Arg Leu Ala Arg Gly Gln Lys Ala Lys Ala Lys Ser Glu Met Arg Glu.Vesicle preparation
SR vesicles were isolated from the back and leg muscles of New
Zealand White rabbits using methods described by Saito et al. (1984)
with minor modifications (Ahern et al., 1994
, 1997a
). Native FKBP12+ TC
vesicles were obtained from the 38%/45% sucrose interface after
sucrose gradient centrifugation. FKBP12 was "stripped" from TC
vesicles by incubating the vesicles with 20 µM rapamycin for 20 min
at 37°C, followed by centrifugation at 540,000 × g
(and then resuspension) to remove rapamycin and the FKBP12-rapamycin complex. The amount of FKBP12 remaining bound to the TC vesicles was
assessed by immunostaining Western blots of the vesicles with anti-peptide antibodies raised against peptides corresponding to the
N-terminal sequence of FKBP12. The incubation procedure with rapamycin
removed all detectable FKBP12 from each of the 14 preparations used in
the present experiments. "FKBP12+-incubated" vesicles, incubated
for 20 min at 37°C in the absence of rapamycin, retained an amount of
FKBP12 similar to that seen in native B4 vesicles. Details of the
FKBP12 "stripping" procedure, production of anti-peptide
antibodies, electrophoresis, and Western blotting are given in Ahern et
al. (1997a)
.
Calcium release from TC vesicles
Extravesicular Ca2+ was monitored at 710 nm with the
Ca2+ indicator, antipyrylazo III, using a Cary 3 spectrophotometer. Identical release experiments, performed at 790 nm,
showed no changes in optical density (OD) that would alter the rate of
Ca2+ uptake measured from recordings at 710 nm. A step
increase in OD upon addition of ruthenium red was seen in recordings at
both 710 nm and 790 nm, and was subtracted from the records shown in Figs. 1 and 2 (see Results). The temperature of the cuvette solution was thermostatically controlled at 25°C and the solution was stirred with a magnetic stirrer. Ca2+ release was measured as
described by Timerman et al. (1993)
. TC vesicles (100 µg protein)
were added to the cuvette, to a final volume of 2 ml, of a solution
containing (in mM): 100, KH2PO4 (pH = 7);
4, MgCl2; 1, Na2ATP; 0.5, antipyrylazo III).
Vesicles were partially loaded with Ca2+ by four sequential
additions of CaCl2, each initially increasing the
extravesicular [Ca2+] by ~7.5 µM (see Figs. 1 and 2).
It was necessary to also suppress Ca2+,Mg2+-ATPase activity after loading (using
thapsigargin, 200 nm; Sagara and Inesi, 1991
), to allow extravesicular
[Ca2+] to increase after activation of the RyR. Peptide
or caffeine were the then added, followed by the RyR blocker ruthenium
red (to a final concentration of 5 µM), to determine whether
Ca2+ release through RyR channels was responsible for
Ca2+ release from SR. The Ca2+ ionophore A23187
(3 µg/ml) was finally added to release the Ca2+ remaining
in the TC vesicles. A calibration curve was established at the start of
each experiment by measuring OD changes in response to four sequential
additions of 12.5 µM CaCl2.
Lipid bilayers
Experiments were carried out at 20-25°C. The techniques are
described in Ahern et al. (1994)
and Laver et al. (1995)
. Bilayers were
formed from phosphatidylethanolamine, phosphatidylserine, and
phosphatidylcholine (5:3:2 w/w) (Avanti Polar Lipids, Alabaster, AL)
across an aperture with a diameter of 200-250 µm in the wall of a
1.0-ml Delrin cup (Cadillac Plastics, Australia). In some experiments
(e.g., Fig. 7) bilayers contained only phosphatidylethanolamine and
phosphatidylcholine (8:2 w/w). In these experiments the negatively charged phosphatidylserine was left out to remove possible effects on
channel activity of bilayer surface potential changes during changes in
ionic composition.
TC vesicles (final concentration, 10 µg/ml) and drugs were added to
the cis chamber. The bilayer potential was controlled, and
single channel activity recorded, using an Axopatch 200A amplifier (Axon Instruments, Foster City, CA). For experimental purposes, the
cis chamber was held at ground and the voltage of the
trans chamber controlled. Bilayer potential is expressed in
the conventional way as Vcis
Vtrans, (i.e.,
Vcytoplasm
Vlumen).
Bilayer solutions
Bilayers were formed and vesicles incorporated into the bilayer
using a cis solution containing 250 mM CsCl (or 230 mM
cesium methanesulfonate (MS) plus 20 mM CsCl), 1 mM CaCl2,
and 10 mM N-tris[hyroxymethyl]methyl-2-aminoethanesulfonic acid
(TES, pH 7.4 with CsOH) and a trans solution containing 50 mM CsCl (or 30 mM CsMS plus 20 mM CsCl), 1 mM CaCl2, and 10 mM TES (pH 7.4). To prevent incorporation of multiple channels into the
bilayer, the cis solution was replaced by perfusion of the
cis chamber as soon as channel activity was observed. The
cis perfusion solution was identical to the initial
cis solution, except that the [Ca2+] was
varied (10
7 M or 10
4 M) as required.
Ca2+ was buffered to 10
7 M or
10
5 M using 1 mM BAPTA; 200 mM CsMS was added to the
trans chamber after channel incorporation to give
symmetrical solutions.
In experiments examining RyR channel activity over a range of peptide
concentrations and at +40 mV and
40 mV, bilayer potential was changed
every 30 s over a 2-min period after each addition of drugs or
peptides to the cis chamber. Control activity was recorded
for 2 min after addition of 200 mM CsMS to the trans chamber. Activity was then recorded for 2 min after cis
additions of 2 mM Na2ATP, 4 mM MgCl2, or 2 mM
MgCl2 and then after each aliquot of peptide (three to
eight different peptide concentrations were examined in each channel).
Peptides were perfused out of the cis chamber, and the
channels were reexposed to Na2ATP plus MgCl2
and then finally to ruthenium red (10-80 µM). In some experiments 5 mM Ca2+ and 250 mM or 500 mM mannitol were added to the
cis solution to aid vesicle incorporation.
Recording and analysis of single channel activity
Currents were filtered at 1 kHz (10-pole low-pass Bessel,
3
dB) and digitized at 5 kHz. Analysis of single channel records (using
Channel 2, developed by P. W. Gage and M. Smith)
yielded channel open probability (Po), frequency
of events (Fo), open times, closed times, and
mean open or closed times (To or
Tc) as well as mean current (I'). The
event discriminator was set above the baseline noise at ~20% of the
maximum current, rather than the usual 50%, so that openings to both
subconductance and maximum conductance levels were included in the
analysis. Channel activity was analyzed over two 30-s periods of
continuous activity at +40 mV and two 30-s periods of continuous
activity at
40 mV.
Values for the peptide concentration required for 50% activation
(AC50) and for 50% inhibition (IC50) of mean
current (I') were obtained from graphs of I' as a
function of peptide concentration, [P] (Figs. 5 and 6). Some data
were fitted with the equation
|
Statistics
Average data are given as mean ± SEM. The significance of
the difference between control and test values was tested 1) using a
Student's t-test, either one- or two-sided and either for
independent or paired data, as appropriate; or 2) using the
nonparametric "sign" test (Minium et al., 1993
). Differences were
considered to be significant when p
0.05.
| |
RESULTS |
|---|
|
|
|---|
Peptide A1 releases Ca2+ from terminal cisternae
The ability of peptide A1 to release Ca2+ from native
FKBP12+ TC vesicles was examined. As previously reported (El-Hayek et al., 1995
; El-Hayek and Ikemoto, 1998
), A1 released Ca2+
from TC. In the present experiments, extravesicular
[Ca2+] increased when 200 nM thapsigargin was added to
the cuvette after loading the SR with Ca2+ (Fig. 1,
A and D).
|
The rate of Ca2+ release with thapsigargan, just before adding the peptide, was ~55 nM/mg/min. Addition of peptide NB did not alter the rate of Ca2+ release, A1S induced a small increase in Ca2+ release, and A1 caused a larger increase (Fig. 1, A-C). Ruthenium red (10 µM) stopped Ca2+ release, if added while extravesicular [Ca2+] was increasing (Fig. 1, A and D), suggesting that the Ca2+ release after addition of thapsigargin (Fig. 1 D), and activated by peptides A1 and A1S (Fig. 1 A), was through RyR channels. The rate of Ca2+ release induced by peptide A1 (maximum rate after A1 addition minus the rate in the presence of thapsigargin) of ±8 nmol/mg/min with 36 µM A1 (n = 8) was significantly greater (p = 0.007) than the 56 ± 10 nmol/mg/min with 36 µM A1S (n = 6, Fig. 1 E).
Activation by A1S suggests that peptides containing positively charged
residues in any sequence can induce Ca2+ release from SR,
via activation of RyRs. This observation is consistent with the ability
of polylysine to release Ca2+ from SR (El-Hayek and
Ikemoto, 1998
).
Ser687 is not essential for peptide activation of Ca2+ release from SR
Surprisingly, and in contrast to results obtained with the
full-length II-III loop peptide (Lu et al., 1995
), the
Ser687 Ala substitution increased the ability of peptide A
to activate Ca2+ release from native FKBP12+ TC vesicles.
Ca2+ release induced by A2 was significantly
(p < 0.05) greater than that induced by peptide A1 and
increased to 191 ± 38 nM/mg/min (n = 11) with 29 µM peptide (filled circles, Fig. 1 F). As with A1, the A2-induced Ca2+ release from SR was substantially
reduced by 10 µM ruthenium red (Fig. 1 D) and was thus
through RyR channels.
Ca2+ release with A1 is less after FKBP12 removal
The experiments were repeated with FKBP12+-incubated and with
FKBP12-stripped TC vesicles. FKBP12-stripped vesicles required longer
loading times than native or FKBP+-incubated vesicles (12 of 12 preparations) as expected from the greater RyR activity after FKBP12
removal (Ahern et al., 1994
, 1997a
; Table 4). Since the rate of
depletion of extravesicular Ca2+ is equal to the rate of
Ca2+ uptake minus the rate of Ca2+ release,
load time increases if release increases. The time allowed for loading
was increased to ~4 min between each addition of CaCl2 for both FKBP12+-incubated and FKBP12-stripped TC (prepared in parallel
from the same native TC preparation). Data were obtained from vesicles
from at least three different preparations. The amount of
Ca2+ loaded, determined from the difference between the OD
after the last load step and the OD 4 min after A23187 addition, was
94.0 ± 0.3% (n = 25) of the Ca2+
added to the extravesicular solution for FKBP12+-incubated and 93.1 ± 0.7% (n = 22) in FKBP12-stripped
vesicles. Peptide A1 (36 µM) was significantly less effective at
releasing Ca2+ from FKBP12-stripped TC (Fig.
2 B) than from the
FKBP12+-incubated TC (Fig. 2 A) at all peptide
concentrations (Fig. 2 C).
|
The reduced Ca2+ release from FKBP12-stripped vesicles might have been due to factors other than the absence of FKBP12. For example, the number of vesicles containing active RyR channels might have been reduced after FKBP12 removal. To test this possibility, the amount of Ca2+ that could be released through RyR channels ("releasable Ca2+") was measured by adding 5 mM caffeine after thapsigargin, and expressing the increase in extravesicular [Ca2+] after 6 min as a fraction of the Ca2+ loaded. Releasable Ca2+ was 64 ± 10 5% in FKBP12+-incubated TC and 54 ± 4% in the FKBP12-stripped TC (each number is the average from two different preparations). The effect of FKBP12 removal on the ability of the TC to release Ca2+ in general was examined by looking at the release in response to 0.5 mM caffeine (a submaximal concentration). The maximum rate of Ca2+ release in response to caffeine was expressed as a fraction of the releasable Ca2+. The rates were 13 ± 3%/min (n = 2) for FKBP12+-incubated TC and 12 ± 1%/min (n = 2) for FKBP12-stripped TC. Thus the rates of release in response to caffeine were not influenced by FKBP12 removal.
Rates of A1-activated Ca2+ release were adjusted for differences in the amounts of releasable Ca2+ between FKBP12+-incubated and FKBP12-stripped TC (Fig. 2 D). The A1-activated Ca2+ release from the FKBP12-stripped RyRs remained significantly less than that from FKBP12+-incubated RyRs at all peptide concentrations. The smaller peptide-induced Ca2+ release from the FKBP12-stripped vesicles suggests that FKBP12 facilitates the activation of RyRs by the II-III loop peptides.
Addition of peptide NB to one pair of stripped and FKBP12+-incubated vesicle preparations did not evoke Ca2+ release (Fig. 2 C, inset); the apparent negative release is due to the fact that the release in the presence of thapsigargin became slower with time, so that subtraction of the latter part of the record from the initial part gave a negative rate.
Effects of peptide A1 on single RyR channels at different cytoplasmic [Ca2+]
Single RyR activity
Peptide A1 (6.5 nM to 32.5 µM) was added to the cis chamber, with 250/250 mM Cs+ (cis/trans), a [Ca2+] of 10
7M, 10
5M, or
10
4M (cis) and 10
3 M
(trans), 2 mM cis Na2ATP, and 2 or 4 mM MgCl2, with bilayer potentials of
40 mV or +40 mV. A1
had excitatory and inhibitory effects on FKBP12+ native channels (Fig.
3).
|
40 mV with 100 nM or 100 µM cis
Ca2+ increased with 650 nM to 32.5 µM cis A1,
with no change in the maximum open channel conductance (Fig. 3,
A and B). Inhibition by 6.5 µM A1 (Fig. 3
A) was apparent at +40 mV, with fewer openings to the
maximum conductance. There were substantially fewer openings at +40 mV
during strong inhibition by 32.5 µM A1 and long openings (>1 s) to
low submaximal conductance levels (Fig. 3 B). Channels recovered from the inhibitory effects of the peptide within 15 s
after perfusion of the cis chamber with peptide-free
cis solution. Channel activity remained higher than control,
especially at
40 mV, for 3-7 min after washout. Activity declined at
longer times after washout. Thus inhibition by peptide A1 is rapidly
reversible, while activation is less reversible.
Effect of peptide A on the mean current through RyRs
A1 increased mean current through native FKBP12+ RyR channels at
40 mV in 17 of 17 bilayers (100 nM, 10 µM, and 100 µM
cis Ca2+). The greatest average peptide
A1-induced increase (~6-fold) in mean current (I') through
RyRs occurred at
40 mV with 100 nM cis Ca2
(Fig. 4 A and Table
1).
|
|
Average normalized I' at
40 mV increased with A1 between
6.5 nM and 32.5 µM, reaching a maximum with ~6.5 µM peptide with half-maximum concentration between 65 and 650 nM at each cis
[Ca2+]. I' at +40 mV also increased with
[A1] at 100 nM and 10 µM cis Ca2+ (Fig. 4,
A and B), but fell below control with A1 > 6.5 nM when cis [Ca2+] was 100 µM, where
inhibition depressed I' below control values with a
half-maximum [A1] of ~0.65 µM. It is likely that the decline in
activation at higher peptide concentrations under the other conditions
can be attributed to inhibition.
Activation by A1 overcame Mg2+ inhibition of RyRs. Data for
100 nM and 100 µM cis Ca2+ were obtained in
the presence of 2 mM Na2ATP and 2 mM MgCl2, with a free Mg2+ of 0.6 mM, which inhibits RyRs by >50%
(Laver et al., 1997a
, b
). Data for 10 µM cis
Ca2+ were obtained with either 2 mM MgCl2
(n = 5) or 4 mM MgCl2 (n = 3, with a free Mg2+ of 2.1 mM, which inhibits skeletal RyRs
by > 90%). Since 6.5 µM A1 caused similar 2.9 ± 0.9-fold
increase with 2 mM MgCl2 or 3.2 ± 1.3-fold increase
with 4 mM MgCl2, data for the two experiments were pooled
for Fig. 4. A1-induced activation was seen in 13 other bilayers (data
not shown) with 4 mM MgCl2, 2 mM Na2ATP, and
100 µM cis Ca2+.
Single channel characteristics of A1-activated RyRs
During the strongest activation by 6.5 µM A1 at
40 mV with 100 nM cis Ca2+, the open probability
(Po) and open frequency
(Fo) were significantly greater than normal, and
mean closed time (Tc) was significantly reduced
(Table 1). Po and Fo at
40 mV were similarly increased by 6.5 µM peptide when
cis [Ca2+] was 100 µM. In contrast, with
activating 10 µM cis Ca2+, mean open time
(To) at
40 mV increased, while
Fo was unaffected and indeed fell in two of the
five channels. Although the changes in parameter values
(I', Po,
Fo, To, and
Tc) for most individual channels at +40 mV were
in the same direction as those at
40 mV, the average changes were
significant only with 10 µM cis Ca2+ (Table
1). Since inhibition by A1 was strongest at +40 mV (Figs. 3 and 4
above), it presumably reduced the degree of activation at this potential.
Removal of peptide A1 enhances RyR activity
Activity often increased further after A1 was perfused out of the
cis chamber. Average I' and
Po were significantly greater than control
(Table 1) after peptide removal, with all cis
[Ca2+]s at
40 mV, while I',
Po, Fo, and
To were significantly greater than control, and
Tc significantly less, at +40 mV with 100 nM or
10 µM cis Ca2+ (Table 1). As in the presence
of A1, the greatest relative increase in I' after perfusion
was at
40 mV with 100 nM cis Ca2+, where
I' was double that before 32.5 µM A1 washout and
~13-fold greater than control. This result suggests that peptide A is
rapidly removed from the blocking site after washout, but that it
remains bound to the activation site. Furthermore, the increase in
channel activity with A1 removal suggests that the degree of activation in the presence of A1 was suppressed by the simultaneous inhibitory action of the peptide. Data at +40 mV for the three cis
[Ca2+]s were pooled to more clearly see the effects of
activation or inhibition by peptide A1 and peptide washout (Table
2).
|
There was a significant increase Fo with 6.5 µM A1 (reflecting activation), while Fo fell with 32.5 µM A1 (reflecting inhibition). Washout of 32.5 µM A1 resulted in significant increases in I', Po, Fo, and To, and a significant decrease in Tc (reflecting recovery from inhibition). This result remains consistent with the hypothesis that peptide A is rapidly removed from its blocking site, but not from its activation site, after washout.
Neither scrambled A1 (A1S) nor NB activates RyRs
The strong activation and inhibition of RyR channels induced by
peptide A1 were not seen with A1S (Fig. 4 D). Similarly,
I' was 0.79 ± 0.24 under control conditions and
0.92 ± 0.26 (n = 6) after addition of 9.3 µM of
NB to the cis side of RyRs at +40 mV with 100 µM
cis Ca2+. Po,
To, Tc, and
Fo were also unaffected by NB. Curiously, a small inhibition of channel activity was seen with A1S. I'
(+40 mV) was less than control in six of seven bilayers with 62 nM and
620 nM cis A1S, and in seven of seven bilayers with 6.2 µM cis A1S. A fall in I' at
40 mV was also seen in
four of seven bilayers after adding 6.2 µM A1S. The average data in
Table 3 show that 6.2 µM A1S causes a
significant reduction in To at
40 mV as well
as significant reductions in Po,
Fo, and To, or increase in Tc at +40 mV (Table 3).
|
It is likely that interactions between the positively charged residues in A1 and negative charges in the channel pore cause the strong channel block by A1 (see Discussion below). The clustered positive charges in the C-terminus of A1 presumably provide a high positive charge density that is effective in blocking the channel. The more diffuse charges in A1S may interact less effectively with the same negatively charged sites in the channel pore to give the weak channel block seen in Fig. 4 and Table 3.
Peptide A2 activates and inhibits native FKBP12+ channels
The Ser687 Ala substitution did not alter the overall ability of peptide A to activate or inhibit native FKBP12+ RyRs. However, A2 activated RyRs at considerably lower peptide concentrations (AC50 between 3.6 and 7.25 nM, Fig. 5), than those required for activation by A1 (AC50 of 65-650 nM, Fig. 4 above).
|
Although the affinity for A2 was higher than that for A1, the degree of activation induced by the two peptides was similar (~2.5-fold with 10 µM or 100 µM cis Ca2+). These results are consistent with the ability of peptide A2 to release Ca2+ from native FKBP12+ SR vesicles (above). A2 also overcame inhibition of RyRs by 0.6 mM free Mg2+ (with 2 mM MgCl2 in the 10 µM cis Ca2+ solution, n = 6), or 2.1 mM free Mg2+ (with 4 mM MgCl2 in the 100 µM cis Ca2+ solution, n = 12).
The affinity of the peptide for the inhibition site was also increased by the Ser687 Ala substitution. The IC50 at +40 mV was ~360 nM with 10 µM and 100 µM cis Ca2+. The cis [Ca2+]-dependence of peptide A2-inhibition differed from that with A1. A2 inhibited at +40 mV with 10 µM cis Ca2+ (dropping I' to ~28% of control, Fig. 5 A), and weaker inhibition at 100 µM cis Ca2+, with I' falling only to control levels (Fig. 5 B).
Minimal peptide A-induced activation in FKBP12-stripped RyRs
In contrast to strong activation of native FKBP12+ channels by
peptide A1 (Figs. 3 and 4), activity of FKBP12-stripped RyRs at
40 mV
was only slightly greater than normal after exposure to 0.65 µM or
32.5 µM peptide A1 with 100 nM cis Ca2+ (Fig.
6 A), and did not increase
after peptide addition with 10 µM cis Ca2+, at
either
40 mV or +40 mV (Fig. 6 B).
|
The control activity of the FKBP12-stripped channels (Fig. 6,
A and B) was greater than that of native FKBP12+
channels (e.g., Fig. 3 above) as expected (Ahern et al., 1994
). More
than one channel was active in most bilayers containing FKBP12-stripped RyRs (Fig. 6, A and B) and long openings to low
submaximal conductance levels were apparent, particularly at
40 mV
(Fig. 6 A). I' (the mean current through the
bilayer divided by the number of channels in the bilayer) during
control activity at each cis [Ca2+] was
greater in FKBP12-stripped RyRs than in FKBP12+ RyRs (Table 4).
|
An increase in activity at
40 mV was seen in 7 of 10 FKBP12-stripped
RyRs with 65 nM to 32.5 µM A1 with 100 nM cis
Ca2+, but was seen in only 3 of the 10 RyRs at +40 mV. On
average, I' at
40 mV (100 nM cis
Ca2+) showed a significant 21% increase after addition of
65 nM to 32.5 µM A1 (Fig. 7
A), compared with the 600% increase seen in native FKBP12+
RyRs.
|
Activity fell in all bilayers when
65 nM A1 was added with 10 µM
cis Ca2+ (n = 7) or 100 µM
cis Ca2+ (n = 3) and average
normalized I' was less than control at both +40 mV and at
40 mV (Fig. 7, B and C). The fall in
I' at
40 mV and +40 mV was significant when 32.5 µM A1
was added with 10 µM cis Ca2+ and when [A1]
was
0.65 µM with 100 µM cis Ca2+. In
contrast to FKBP12-stripped channels, FKBP12+-incubated RyRs were
strongly activated by A1 at +40 mV and
40 mV, with 100 nM cis Ca2+ (Fig. 7 D). Therefore, the
loss of activation in FKBP12-stripped channels was not due to the
incubation procedure. Inhibition without activation was seen in another
seven FKBP12-stripped RyRs when 65 nM to 32.5 µM A1 was added with
100 µM cis Ca2+, 2 mM Na2ATP, and
4 mM MgCl2. The results confirm the Ca2+
release studies and show that activation of native RyRs by peptide A1
depends on the presence of the FK506-binding protein.
Peptide A block of FKBP+ and FKBP-stripped RyRs
Effects of ATP and Mg2+
The block of RyRs by peptide A was unexpected because
6.5 µM
of the peptide caused significant ruthenium red-sensitive
Ca2+ release from TC vesicles. The recording conditions
were varied to ascertain whether, in addition to depending on
cis [Ca2+], channel block by peptide A was
influenced by cytoplasmic (cis) ATP or Mg2+.
Block was seen with 100 µM cis Ca2+ in the
absence of ATP or Mg2+ (n = 11) or with 2 mM ATP (without Mg2+, n = 6). Thus channel
block appeared to be independent of ATP or Mg2+ in the
cis solution.
Effect of permeant ions on the inhibition of RyRs by peptide A1
Inhibition of RyR activity by peptide A was stronger at +40 mV than at
40 mV (Figs. 3 and 4). This apparent membrane
potential-dependence might have been due to an effect of membrane
potential per se on peptide binding and channel block, or it could be
due to permeant cations entering the pore from the opposite side of the
channel (i.e., the trans bath). The latter possibility would
suggest a blocking mechanism in which the peptide binds within the
channel pore and is displaced by ion flow from the trans
chamber. To explore this possibility, we measured the effect of varying
the concentration of permeant ions in the trans chamber (at
constant membrane potential) on the inhibition of native FKBP12+ RyR
channels by cis peptide. In these experiments the bilayers
were composed of only neutral lipids (see Methods) to minimize bilayer
surface potentials and possible effects of the trans
solution ionic strength on surface potential and peptide binding. If
charged lipids were used, changes in the ionic composition of the
trans bath could alter peptide binding even if the binding
site was not in the pore. The trans concentration of the
permeant cation, Cs+, but not the impermeant cation,
choline+, had a major effect on the strength of peptide
inhibition (Fig. 8).
|
|
Channel openings to submaximal conductances are resistant to inhibition by peptides A1 and A2
FKBP12+ channels
The reduced channel activity (and I') produced by adding >4 µM A1 was due to fewer channel openings (Table 2), to a reduction in the number of openings to the maximum conductance in native FKBP12+ (Fig. 3; Figs. 8 and 9), and in FKBP12+-incubated channels. The native FKBP12+ RyR in Fig. 9 showed long openings (lasting for >20 ms) to the maximum conductance and to several submaximal conductance levels under control conditions at +40 mV (Fig. 9 A). When 6.5 µM peptide was added, there were only occasional brief openings to the high conductance levels, although long openings to submaximal conductance levels remained and were longer than those in the control record (Fig. 9 B). Channel openings to the maximum conductance recovered when the peptide was perfused out of the cis chamber (Fig. 9 C). The maximum conductance and three of the submaximal levels (at ~11, 33, and 67% of the maximum conductance) that could be seen under all conditions are shown by the broken lines on the records and by the arrows on the histograms. Similar effects of peptide block on openings to the maximum conductance were seen at all cis [Ca2+] tested, and were seen to a lesser extent at
40 mV.
|
FKBP12-stripped channels
The effect of peptide A in preferentially blocking channel openings to maximum conductance levels was also apparent in FKBP12-stripped channels that demonstrated considerable submaximal conductance activity in the absence of peptide. As previously reported for FKBP12-stripped channels (Ahern et al., 1994
40 mV, and with 100 nM and 100 µM
cis Ca2+.
Incidental observations: RyR activation by ATP and inhibition by Mg2+
Addition of 2 mM ATP induced the expected increase in average I' through native FKBP12+ channels at both +40 mV and
40
mV with 100 µM cis Ca2+ (n = 20, Fig. 10). Addition of 4 mM
MgCl2 (2.1 mM free Mg2+) then reduced
I' at positive and negative potentials, but to levels that
remained higher than those before addition of ATP. The response to both
ATP and 4 mM MgCl2 was similar in the 20 normal and 16 FKBP12-stripped channels, although channel activity fell to levels that
were not significantly different from control when 4 mM
MgCl2 was added to the FKBP12-stripped channels at +40 mV
(Fig. 10 B). If 2 mM MgCl2 was added
simultaneously with 2 mM Na2ATP (with 0.6 mM free
Mg2+), channel activity remained at levels that were not
significantly different from control or greater than control (Table
6).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
We show here that peptide A (corresponding to the N terminal of
the DHPR II-III loop), at concentrations from 65 nM to 32.5 µM,
activates native RyR channels at
40 mV with cis
[Ca2+]s of 100 nM, 10 µM, and 100 µM. The peptide
also inhibited channel activity in native RyRs and, at >4 µM,
reduced the mean current at +40 mV to less than control levels when
cis [Ca2+] was 100 µM. Activation by peptide
A was expected because it has been shown that the peptide increases
[3H]ryanodine binding to, and releases Ca2+
from, SR vesicles (El-Hayek et al., 1995
). The blocking action of the
peptide was not expected from previous single channel studies on longer
segments of the II-III loop (Lu et al., 1995
), although a decline in
the rate of peptide-activated Ca2+ release from SR is
apparent with higher concentrations of a fragment of the peptide
(El-Hayek and Ikemoto, 1998
).
Peptide A activation of the skeletal RyR
Peptide A activation overcame Mg2+ block of RyR
activity. Mg2+ block reduced RyR activity and suppressed
Ca2+ release through the channel in resting muscle (Lamb
and Stephenson, 1991
). Peptide A activated RyRs in the presence of
~0.6 mM free Mg2+ in Ca2+ release
experiments, or 0.6 mM to 2.1 mM free Mg2+ in single
channel experiments (with 10
7 to 10
4 M
Ca2+). Thus, peptide A-induced activation mimics ECC
insofar as it can overcome Mg2+-inhibition of RyR activity.
The degree of activation of the RyR by peptide A was not as large as
expected for the primary trigger of RyR opening during ECC. Channel
open probability (Po) with 0.65-6.5 µM
peptide remained well below 1.0 (Table 1), while the rate of
Ca2+ release from TC in our experiments, and in the faster
release in stop-flow experiments (El-Hayek and Ikemoto, 1998
), remain slower than Ca2+ release during ECC (Melzer et al., 1987
).
The lower-than-expected activation could indicate that a conformational
change in the II-III loop occurs during ECC, but does not occur when
the peptide is isolated from the remainder of the DHPR and is not under
the influence of the T-tubule membrane potential. Alternatively (or in
addition), the relatively small increase in I' and
Po could be due to the strong concurrent
inhibition. Although inhibition per se was not apparent in SR
Ca2+ release, inhibition could have reduced the degree of
activation (as indicated by the increased activity after removal of
peptide A from the cis chamber).
It is likely that peptide A activation of the RyR depends on the highly
positively charged residues in the C half of the peptide. A smaller
II-III loop peptide containing these arginine and lysine residues (Arg
Lys Arg Arg Lys Met Ser Arg Gly Leu), increases 3H-ryanodine binding and releases Ca2+ from SR
(El-Hayek and Ikemoto, 1998
; Dulhunty et al., 1999
). Thus it is likely
that it is this segment of the II-III loop that binds to skeletal RyRs
at residues 1076-1112 (Leong and Maclennan, 1998
). Skeletal type ECC
also requires region D3, residues 1872-1923 (Nakai et al., 1998a
), and
perhaps region D2 (1342-1403, Yamazawa et al., 1997
) of the RyR. The
involvement of these diverse regions of the RyR indicates a complex
transduction pathway through the channel protein between its
interaction with the DHPR and the ion channel pore. This is not
surprising, given the size and complex structure of the protein
(Radermacher et al., 1994
; Orlova et al., 1996
; Wagenknecht and
Radermacher, 1997
; Wagenknecht et al., 1997
).
Importance of Ser687 in II-III loop activation of RyRs
In our studies, enhanced peptide-induced Ca2+ release
from TC and activation of single RyRs at lower peptide concentrations were seen with the Ser687 Ala substitution. This is in
contrast to the abolition of activation seen with the same substitution
in the full II-III loop (Lu et al., 1995
). However, Ser687
Ala substitution in the entire DHPR
1 subunit does not
alter the ability of the DHPR to support skeletal-type ECC (Nakai et al., 1998b
). The reasons for these conflicting results are not clear.
However, the Ser687 Ala substitution could well produce a
structural change that prevents the full II-III loop from activating
the RyR, but that enhances activation by the shorter peptides. Enhanced
activation may not have been detected within the resolution of the ECC
studies (Nakai et al., 1998b
).
The FK506 binding protein
The ability of peptide A to activate RyRs was substantially
reduced in FKBP12-stripped RyRs. The removal of FKBP12 reduces the
number of RyR openings to the maximum conductance, but does not alter
the regulation of the channel by Ca2+ (Ahern et al.,
1997b
), ATP, Mg2+, or caffeine (see Results). The influence
of FKBP12 on channel activation by A1 is unique among these ligands,
which supports suggestions that FKBP12 plays a role in RyR activation
during ECC (Ahern et al., 1994
, 1997a
; Brillantes et al., 1994
;
Mayrleitner et al., 1994
; Lamb and Stephenson, 1996
).
The putative FKBP12 binding domain at 2407-2520 (Cameron et al., 1997
)
is located on the surface of the RyR that opposes the T-tubule membrane
(Wagenknecht et al., 1997
). Four FKBP12 molecules bind to each RyR,
i.e., one per subunit (Jayaraman et al., 1992
; Timerman et al., 1993
;
Wagenknecht et al., 1996
, 1997
). The II-III loop binding domain must be
located on the same surface of the RyR to enable the DHPR to bind to
the RyR. Since skeletal muscle DHPRs are clumped into tetrads, which
oppose every second RyR (Block et al., 1988
), each subunit of every
second RyR is likely to interact with the II-III loop of one of the
DHPRs in a tetrad. The T-tubule opposing surface of each subunit of the
RyR must contain an FKBP12 binding site and a II-III loop binding site. An interaction between FKBP12 binding and activation of RyRs by the
II-III loop has been suggested by the fact that FK506 can disrupt
depolarization-induced Ca2+ release from the SR (Lamb and
Stephenson, 1996
).
Physiological interactions between the DHPR and the RyR during ECC
It is not known whether the II-III loop is bound to the RyR in
vivo or binding occurs only during ECC. In the latter case, binding
alone could be sufficient to activate the RyR although, as mentioned
previously, the activation produced by peptide binding is not as strong
as might be expected. However, there is evidence that a complex can be
formed between the RyR and DHPR (Marty et al., 1994
; Murray and
Ohlendieck, 1998
). If there is a stable II-III loop-RyR complex,
then RyR activation during ECC could depend on a conformational change
in the II-III loop being transmitted, through the DHPR/RyR interaction
site, to the RyR.
Although studies with synthetic peptides and RyRs in bilayers or
vesicles clearly show that peptide A can activate the calcium release
channel, apparently conflicting results have been obtained from ECC
studies with dysgenic myotubes expressing chimeric DHPRs. It is clear
that the skeletal ECC (independent of external Ca2+)
requires the skeletal II-III loop and will not proceed if the loop
contains the cardiac sequence (Tanabe et al., 1990
). However, when
chimeras are constructed with parts of the II-III loop, skeletal-type ECC proceeds when the A portion contains either the cardiac or skeletal sequence (Nakai et al., 1998b
). Skeletal ECC has an absolute requirement for the skeletal sequence in residues 725-742 (encompassed in the C portion of the II-III loop according to El-Hayek et al., 1995
). Lu et al. (1994
, 1995
) found that both the cardiac and skeletal II-III loops increased ryanodine binding to SR vesicles and
activated RyR channels, suggesting that both the cardiac and skeletal
II-III loops bind to the skeletal RyR, and in agreement with the ECC
studies. The II-III loops presumably bind to the RyR at the A region,
which contains several arginine and lysine residues in both the
skeletal and cardiac isoforms.
One hypothesis that could explain most observations is that the positively charged A region of the II-III loop binds to the RyR, causing an increase in RyR activity. Full activation of the RyR requires a conformational change at the binding site, which is initiated by the voltage sensor in the S4 segment of the DHPR and is transmitted through the C region (725-742) of the II-III loop. Either the skeletal or cardiac sequence of the II-III loop binds to (or interacts with) the skeletal RyR. However, skeletal-type ECC requires transmission of T-tubule depolarization to the II-III loop/RyR interaction site, and this can only proceed if residues 725-742 contain the skeletal DHPR sequence.
Peptide A inhibition of the skeletal RyR
The peptide inhibition site is distinct from the II-III loop activation site because 1) inhibition is greatest at 100 µM cis Ca2+, while activation is greatest at 100 nM cis Ca2+; 2) inhibition, but not activation, depends on the direction of current flow; and 3) unlike activation, inhibition is not disrupted by removing FKBP12. The fact that inhibition by cis peptide A was reduced when Cs+ flows from trans to cis is consistent with the peptides blocking by binding to the pore or vestibule of the RyR, since Cs+ could enter the pore from the trans bath and compete with the peptide for its binding site. This hypothesis is supported by the fact that high trans [choline+], which does not pass through RyR channels, did not affect cis peptide inhibition. The sensitivity of peptide block to the flow of permeant cations may also account for its voltage-dependence, since at negative potentials the electric field in the pore will favor cation permeation from the trans side, whereas positive potentials will oppose it.
In contrast to peptide A, the full-length DHPR II-III loop has not been
reported to inhibit RyR activity (Lu et al., 1994
, 1995
). Failure of
the full-length II-III loop to block can be explained if the blocking
site is in the channel pore, since the bulk of the longer peptide could
restrict its access to the blocking site. The observation is consistent
with the hypothesis that there are separate inhibition and activation sites.
Permeant ions flowing from the opposite side of a channel have been
shown elsewhere to reduce the binding of pore blocking peptides [e.g.,
charybdotoxin block of the Ca2+-activated K+
channel (MacKinnon and Miller, 1988
)]. A toxin that blocks the K+ channel pore also blocks RyRs, possibly because
positively charged arginine and lysine residues in the peptides bind to
negative charges near the channel pore (Mead et al., 1998
). Peptide A, also rich in arginine and lysine residues, may bind to the RyR at a
site similar to the toxin binding site.
Two factors that need to be considered in developing a model for
peptide binding in the channel pore are 1) inhibition depends on
cis [Ca2+] and is greatest at 100 µM
cis Ca2+; and 2) inhibition preferentially
targeted maximal conductance openings, while leaving openings to
submaximal conductances intact. The blocking mechanism must differ from
ryanodine block, which causes equal depression of all conductance
levels (Ahern et al., 1997a
). The sensitivity of peptide inhibition to
direction of flow of permeant ions may account for the fact that
inhibition was not apparent in vesicle experiments, since
Ca2+ flow from the lumen to cytoplasm (trans to
cis) would reduce peptide-induced inhibition. The
cis [Ca2+]-dependence of inhibition would also
reduce the efficacy of inhibition in the vesicle experiments since the
extravesicular [Ca2+] was considerably less than 100 µM
during maximum rates of release. Although inhibition dominated the
effect of peptide A on RyRs in bilayers, it might not reflect a
physiological action of the DHPR, since the II-III loop in vivo is
physically constrained by the DHPR's location in the T-tubule membrane
and may not be free to enter the channel pore. However, inhibition must
be considered when studying the action of the II-III loop, or loop
peptides, on Ca2+ release from SR or on single RyR channels.
In conclusion, we have shown that peptides corresponding to an amino acid sequence in the N-terminal region of the II-III loop of the skeletal muscle DHPR activate ryanodine-sensitive Ca2+ release from SR vesicles and activate single RyR channels incorporated into lipid bilayers. Study of RyR channel activation by the peptide is complicated by a competing strong inhibitory action of the peptide. The results show that activation of RyRs by the peptide is not dependent on Ser687 in the DHPR II-III loop and that activation of the RyR by the peptide is facilitated when FKBP12 is bound to the RyR. These observations suggest that activation of the RyR by the DHPR II-III loop requires a complex sequence of signals passing from the II-III loop binding site to the RyR channel pore. The inhibitory action of peptide binding could provide a useful tool to probe the RyR pore, but inhibition is unlikely to be relevant to RyR function in vivo.
| |
ACKNOWLEDGMENTS |
|---|
The authors are grateful to Joan Stivala, Glen Whalley, and Bernie Keys for their assistance.
Professor Gallant was supported by grants from the National Institutes of Health and National Science Foundation. Dr. D. R. Laver was supported by a grant from the Australian National Health and Medical Research Council.
| |
FOOTNOTES |
|---|
Received for publication 22 July 1998 and in final form 5 April 1999.
Address reprint requests to Dr. A. F. Dulhunty, John Curtin School of Medical Research, Australian National University, P.O. Box 334, Canberra, ACT 2601, Australia. Tel.: 61 6 249 4491; Fax: 61 6 249 4761; E-mail: angela.dulhunty{at}anu.edu.au.
| |
REFERENCES |
|---|
|
|
|---|